Gray NS - Search Results

1

Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer.

Terai H, Tan L, Beauchamp EM, Hatcher JM, Liu Q, Meyerson M, Gray NS, Hammerman PS. Terai H, et al. Among authors: gray ns. ACS Chem Biol. 2015 Dec 18;10(12):2687-96. doi: 10.1021/acschembio.5b00655. Epub 2015 Sep 25. ACS Chem Biol. 2015. PMID: 26390252 Free PMC article.

2

Allosteric inhibitors of Bcr-abl-dependent cell proliferation.

Adrián FJ, Ding Q, Sim T, Velentza A, Sloan C, Liu Y, Zhang G, Hur W, Ding S, Manley P, Mestan J, Fabbro D, Gray NS. Adrián FJ, et al. Among authors: gray ns. Nat Chem Biol. 2006 Feb;2(2):95-102. doi: 10.1038/nchembio760. Epub 2006 Jan 15. Nat Chem Biol. 2006. PMID: 16415863

3

Chemical proteomics identifies unanticipated targets of clinical kinase inhibitors.

Peters EC, Gray NS. Peters EC, et al. Among authors: gray ns. ACS Chem Biol. 2007 Oct 19;2(10):661-4. doi: 10.1021/cb700203j. ACS Chem Biol. 2007. PMID: 18041816

4

Discovery of selective aminothiazole aurora kinase inhibitors.

Andersen CB, Wan Y, Chang JW, Riggs B, Lee C, Liu Y, Sessa F, Villa F, Kwiatkowski N, Suzuki M, Nallan L, Heald R, Musacchio A, Gray NS. Andersen CB, et al. Among authors: gray ns. ACS Chem Biol. 2008 Mar 20;3(3):180-92. doi: 10.1021/cb700200w. Epub 2008 Feb 29. ACS Chem Biol. 2008. PMID: 18307303

5

Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.

McDermott U, Iafrate AJ, Gray NS, Shioda T, Classon M, Maheswaran S, Zhou W, Choi HG, Smith SL, Dowell L, Ulkus LE, Kuhlmann G, Greninger P, Christensen JG, Haber DA, Settleman J. McDermott U, et al. Among authors: gray ns. Cancer Res. 2008 May 1;68(9):3389-95. doi: 10.1158/0008-5472.CAN-07-6186. Cancer Res. 2008. PMID: 18451166

6

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.

Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, Choi HG, Kim J, Chiang D, Thomas R, Lee J, Richards WG, Sugarbaker DJ, Ducko C, Lindeman N, Marcoux JP, Engelman JA, Gray NS, Lee C, Meyerson M, Jänne PA. Koivunen JP, et al. Among authors: gray ns. Clin Cancer Res. 2008 Jul 1;14(13):4275-83. doi: 10.1158/1078-0432.CCR-08-0168. Clin Cancer Res. 2008. PMID: 18594010 Free PMC article.

7

Activating mutations in ALK provide a therapeutic target in neuroblastoma.

George RE, Sanda T, Hanna M, Fröhling S, Luther W 2nd, Zhang J, Ahn Y, Zhou W, London WB, McGrady P, Xue L, Zozulya S, Gregor VE, Webb TR, Gray NS, Gilliland DG, Diller L, Greulich H, Morris SW, Meyerson M, Look AT. George RE, et al. Among authors: gray ns. Nature. 2008 Oct 16;455(7215):975-8. doi: 10.1038/nature07397. Nature. 2008. PMID: 18923525 Free PMC article.

8

Targeting cancer with small molecule kinase inhibitors.

Zhang J, Yang PL, Gray NS. Zhang J, et al. Among authors: gray ns. Nat Rev Cancer. 2009 Jan;9(1):28-39. doi: 10.1038/nrc2559. Nat Rev Cancer. 2009. PMID: 19104514 Review.

9

An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1.

Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, Reichling LJ, Sim T, Sabatini DM, Gray NS. Thoreen CC, et al. Among authors: gray ns. J Biol Chem. 2009 Mar 20;284(12):8023-32. doi: 10.1074/jbc.M900301200. Epub 2009 Jan 15. J Biol Chem. 2009. PMID: 19150980 Free PMC article.

10

FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML.

Weisberg E, Barrett R, Liu Q, Stone R, Gray N, Griffin JD. Weisberg E, et al. Drug Resist Updat. 2009 Jun;12(3):81-9. doi: 10.1016/j.drup.2009.04.001. Epub 2009 May 20. Drug Resist Updat. 2009. PMID: 19467916 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

542 results

Search Page